Eileen Marshall

Cooley advised Datadog (Nasdaq: DDOG), a monitoring and security platform for cloud applications, on its acquisition of Eppo, a feature flagging and experimentation platform that will tightly integrate with Datadog’s existing product analytics suite.

Cooley advised Araris Biotech, a Swiss biotechnology company developing next-generation antibody-drug conjugates, on its definitive agreement to be acquired by Japan-based Taiho Pharmaceutical for up to $1.14 billion in cash.

Cooley advised the special committee of Checkpoint Therapeutics’ (Nasdaq: CKPT) board of directors in connection with Checkpoint’s definitive agreement to be acquired by Sun Pharmaceutical Industries (NSE: SUNPHARMA) for up to $416 million in cash and contingent value rights.

Cooley advised Katy Hearn and Haydn Schneider, co-founders of Alani Nu, in connection with Celsius Holdings’ (Nasdaq: CELH) definitive agreement to acquire the company for $1.8 billion in cash and stock.

Cooley advised Tempus AI (Nasdaq: TEM), a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, on its $300 million incremental term loan and revolving credit commitments under its credit agreement with Ares Capital Corporation. Partners Addison Pierce and Michael Tollini led the Cooley team advising Tempus, which also included partner Eileen Marshall and associates JJ Meng, Stevie Yu and Yichao Zhang.